Adequan shortage imminent due to FDA-driven factory renovations

source-image
May 30, 2013
By dvm360.com staff

Supplies of Adequan i.m., a polysulfated glycosaminoglycan (PSGAG) approved by the Food and Drug Administration (FDA) to treat joint problems in horses, are expected to be limited during the coming months due to renovations at the company’s Shirley, N.Y., manufacturing facility.

“Our factory in N.Y. has undergone a significant renovation to meet enhanced quality standards and address observations of the FDA,” states Luitpold Pharmaceuticals in a May release. “This has resulted in the depletion of our existing inventories. We have carefully managed supply to allocate inventory optimally, but the product will be out of stock for a short period of time.”

Luitpold expects to resume shipments of the 5-ml product in early July, followed by the 50-ml product in August. For updates on expected release dates, visit adequan.com.